MoST-CIRCUIT is the first clinical trial to prospectively investigate immunotherapy using anti-PD-1/CTLA-4 blockade in patients with advanced dMMR/MSI-H non-colorectal cancers. Here, CTLA4 is linked to colorectal cancer.